Beyond the randomized clinical trials comes the real-world evidence

Sofia, November 14, 2022 – Dr. Gergana Shalamanova from the Oncology Center in Plovdiv showed the interesting comparison of Real-world Evidence (RWE) vs. Randomized Clinical Trials at the Second National Congress in Dermatooncology.

The results of BRAF inhibitors’ registrational clinical trials have been externally validated to the real-world population of patients with BRAF+ melanoma using Sqilline Danny Platform.

The efficacy of certain targeted therapies in BRAF+ melanoma patients is better in real-world settings compared to the results of two randomized clinical trials with differences of:

  • 20 and 24% in progression-free survival (PFS) at 12 months;
  • 12 and 13% in overall survival (OS) at 12 months.

Beyond the randomized clinical trials comes the real-world evidence… Danny Platform compares both and shows higher efficacy of targeted therapies in real-world BRAF+ melanoma patients,” said Dr. Shalamanova.

These findings open discussion for the wider use of technology in generating Real-world Evidence (RWE) to assess treatment outcomes in real-world settings.

Sqilline Danny Platform proves to be a highly effective technology to collect, process, and analyze Real-world Data (RWD) from Electronic Health Records (EHRs) and turning it into RWE.

Curious to learn more? Get in touch with our team! https://sqilline.com/contact-us/

Share this article:

More News & Highlights

News

10 YEARS NATIONAL COUNCIL ON PRICES AND REIMBURSEMENT OF MEDICINAL PRODUCTS

Sqilline is proud to celebrate this event as the trusted technology solution provider utilising REAL-WORLD EVIDENCE to IMPROVE ONCOLOGY CARE on a NATIONAL LEVEL  ...

Read more...

News

Artificial intelligence detects first patients with rare neurological disease. Danny Platform enables screening and early diagnosis for high-risk patients

Interview with Prof. Milanov and Prof. Bogdanova, published in Kapital Health, December 2022 Prof. Milanov Prof. Dr. Ivan Milanov, Ph.D., is the Executive Director of...

Read more...

Case Studies

First patients diagnosed with rare disease with assist of AI algorithm are a fact

Sqilline and a leading pharmaceutical company have partnered to apply an AI algorithm and track high-risk patients for the rare disease of Transthyretin amyloid polyneuropathy (TTR)....

Read more...